GO
Loading...

Sanofi SA

More

  • French and Benelux stocks-Factors to watch on Oct 8 Monday, 8 Oct 2012 | 1:28 AM ET

    Britain will block the proposed $45 billion merger between EADS and BAE Systems if key "red line" priorities are not met, defence minister Philip Hammond said on Sunday, just three days before a deadline for detailing the deal.

  • *Unions predict more layoffs than 900 cuts mooted by Sanofi. PARIS, Oct 5- Sanofi's plan to restructure its research operations in France could lead to more job losses than the 900 layoffs mooted by the drugmaker, union representatives said.

  • PARIS, Oct 5- French automaker Renault plans to build more than 70 percent of its Clio subcompacts in Turkey, union sources said, in a shift abroad that could inflame tensions with workers and the government, its biggest shareholder.

  • French and Benelux stocks-Factors to watch on Oct 5 Friday, 5 Oct 2012 | 1:13 AM ET

    EADS and BAE Systems have edged closer towards winning political backing for a $45 billion merger amid positive signals from Britain and France, but German misgivings over control remain a major hurdle, sources close to the talks said.

  • "We anticipate that Denmark- based Novo Nordisk A/S, already the global market leader in diabetic treatments, could jump into the top 10 global pharmaceutical companies in revenue terms over the next few years, while presently it is still a midsize company compared with its peers and specializes almost exclusively on diabetes treatments," said Standard& Poor's credit analyst Olaf Toelke.

  • News Summary: Bristol-Myers, Sanofi alter alliance Wednesday, 3 Oct 2012 | 3:18 PM ET

    NEW DEAL: Bristol-Myers Squibb and France's Sanofi are revamping their longtime partnership marketing some of their best-selling medications, blood thinner Plavix and blood pressure drugs Avapro and Avalide. THE TERMS: Bristol-Myers will keep selling Plavix in the U.S. through December 2019.

  • Bristol-Myers, Sanofi revamp Plavix sales alliance Wednesday, 3 Oct 2012 | 11:41 AM ET

    TRENTON, N.J.-- Bristol-Myers Squibb Co. and Sanofi SA said Wednesday that they are restructuring their longtime partnership selling popular heart medications, now that their sales are plunging due to recent, widespread competition from generic versions.

  • *Bristol to return rights to Plavix, Avapro to Sanofi. *Sanofi to make $200 mln terminal payment to Bristol in 2018. *Sanofi shares down 0.8 pct By James Regan.

  • LONDON, Oct 3- European stocks were set for a slightly lower open on Wednesday as new gloomy economic data and uncertainty about Spain's debt crisis eclipsed underlying optimism about coordinated monetary support from central banks across the world.

  • Sanofi, Bristol shake up alliance as patents end Wednesday, 3 Oct 2012 | 1:46 AM ET

    This will give Sanofi sole commercial control of the two treatments, although Bristol-Myers will keep rights to Plavix in the United States and Puerto Rico. In return, Sanofi will pay Bristol-Myers royalty payments through 2018 on its sales of branded and unbranded Plavix worldwide, excluding the U.S. and Puerto Rico, and on sales of Avapro/Avalide.

  • French and Benelux stocks-Factors to watch on Oct. 3 Wednesday, 3 Oct 2012 | 12:59 AM ET

    Ipsen said that Inspiration Biopharmaceuticals had not raised third-party financing by the contractual deadline of Sept. 30 and that it was therefore no longer obligated to pay the additional $12.5 million in exchange for Inspiration equity. The parties continue to explore various options, Ipsen said.

  • PARIS, Oct 3- A quest by President Francois Hollande to show he can halt industrial closures by rescuing two mothballed blast furnaces in northeast France risks backfiring, with industry experts doubting any buyer will come forward. With joblessness at over 10 percent and his ratings in free-fall, Hollande persuaded steel giant ArcelorMittal.

  • PARIS, Oct 2- Sanofi's Lyxumia experimental diabetes treatment can slow down the rate at which food passes and can reduce blood sugar levels after a meal when given in combination with other diabetes drugs, the drugmaker said in a statement on Tuesday.

  • Sanofi says Lyxumia diabetes drug studies positive Tuesday, 2 Oct 2012 | 6:21 AM ET

    PARIS, Oct 2- Sanofi's experimental diabetes treatment Lyxumia can slow down the rate at which food passes and can reduce blood sugar levels after a meal when given in combination with other diabetes drugs, the drugmaker said in a statement on Tuesday.

  • COPENHAGEN, Oct 2- Denmark's Novo Nordisk, the world's biggest insulin producer, said its insulin degludec had shown 43 percent lower rates of night-time low blood sugar levels than glargine from rival drugmaker Sanofi. Novo Nordisk said in a statement the data was presented on Tuesday at the Annual Meeting of the European Association for the Study of Diabetes.

  • PARIS, Oct 2- Sanofi's experimental pill to treat Gaucher disease, a rare inherited condition, has met its main goal in a late-stage trial, the French drugmaker said on Tuesday.

  • LONDON, Oct 2- European shares were set to retreat in early trading on Tuesday after strong gains in the previous session, with uncertainty over the timing of a likely aid request by Spain seen prompting investors to cut their exposure to riskier assets.

  • PARIS, Oct 2- Sanofi's experimental pill to treat Gaucher disease, a rare inherited condition, has met its main goal in a late-stage trial, the French drugmaker said on Tuesday.

  • French and Benelux stocks-Factors to watch on Oct. 2 Tuesday, 2 Oct 2012 | 12:50 AM ET

    CAC-40 futures are 0.7 percent lower at 0620 GMT FRANCE TELECOM. The oil services company said on Tuesday it has signed a lump-sum contract with Murphy Exploration& Production Company for the development of an offshore field in the Gulf of Mexico.

  • LONDON, Oct 1- European shares rebounded from three-week lows on Monday in a technical rally, with price dips and the unsurprising results of a Spanish bank stress test luring investors into the market, but analysts said the bounce was unsustainable. fiscal cliff "of scheduled tax hikes and government spending cuts as well as the situation in Spain.

Most Popular Video

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.

Thursday, 17 Apr 2014 | 11:00 AM ET

Phil LeBeau has the details on the latest rides at this year's New York Auto Show.

Monday, 14 Apr 2014 | 11:43 AM ET

Dr. Steven Horng, Beth Israel Deaconess Medical Center, explains how Google Glass provided crucial support in an emergency situation and helped save a life.